uniQure files BLA and MAA for gene therapy in Huntington's disease
uniQure submitted a Biologics License Application to the FDA and a Marketing Authorisation Application to the MHRA for AMT-130, seeking accelerated approval for Huntington's disease. Both filings are supported by Phase I/II data showing a slowed disease progression.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day